Sartorius AG

Labviva Positions for Next Stage of Commercial Growth with Key Executive Hires

Retrieved on: 
Tuesday, May 2, 2023
Research, Technology, Clinical Trials, Software, Biotechnology, Hardware, Pharmaceutical, Health, Science, Other Science, Cloud, Quotient, Molecular biology, Genzyme, University, Senior, Final good, University of Massachusetts, Harvard University, Quotient Technology, Systems engineering, Marketing strategy, MBA, MIT, CJ Affiliate, Sartorius AG, BBA, Computer, Veeva Systems, Master of Engineering, QA, Google Cloud, Engineering, Harvard Business School, RWTH Aachen Faculty of Mathematics, Computer science, and Natural sciences, Management, Mathematics, One by AOL, Commerce, Datavant

Labviva , the AI-driven life sciences procurement platform, today announced the appointment of three new executives to drive key functions.

Key Points: 
  • Labviva , the AI-driven life sciences procurement platform, today announced the appointment of three new executives to drive key functions.
  • Emily Nault joins Labviva as Senior Vice President, Platform Sales and Commerce, Jonathan Sheffi will join Labviva as Vice President, Strategic Marketing and Neal Karasic as Vice President of Product.
  • "We’re thrilled to welcome Emily, Jonathan, and Neal to the Labviva team to support growing market demand," said Siamak Baharloo, CEO of Labviva.
  • Labviva has seamlessly integrated scientific content and products from hundreds of brands and suppliers, to create a unique and efficient onboarding and purchasing experience.

Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech

Retrieved on: 
Thursday, April 20, 2023
Eye, Sartorius AG, Projection, Public expenditure, CAPEX, EBITDA, Acquisition, Traction, CEST, Growth, Security (finance), Pharmaceutical industry, Risk management, Management

We therefore confirm our outlook for the full year 2023 though the economic environment also in our sector is currently highly uncertain,” said René Fáber, CEO of Sartorius Stedim Biotech.

Key Points: 
  • We therefore confirm our outlook for the full year 2023 though the economic environment also in our sector is currently highly uncertain,” said René Fáber, CEO of Sartorius Stedim Biotech.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this release.
  • René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s business results with analysts and investors in a conference call at 3.30 p.m. CEST on April 20, 2023.

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus

Retrieved on: 
Saturday, April 15, 2023
WP, GMP, DNA, Kirkland & Ellis, Sartorius AG, Partner (business rank), Research, Milbank, Cell, Transfection, Warburg Pincus, Euronext Paris, EBITDA, Jefferies Group, Euronext, Acquisition, Patient, Growth, Jeantet, Gene, Sartorius, J. P. Morgan, Vaccine, Management, Fine chemical, Health care

“We would be excited to join forces with a world class bioprocess market leader as Sartorius Stedim Biotech.

Key Points: 
  • “We would be excited to join forces with a world class bioprocess market leader as Sartorius Stedim Biotech.
  • William Blair acted as financial advisor and Milbank LLP and Jeantet provided legal counsel to Sartorius Stedim Biotech.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies.

EQS-News: SARTORIUS AG: Sartorius to acquire Polyplus

Retrieved on: 
Saturday, April 15, 2023
Vaccine, WP, GMP, DNA, Kirkland & Ellis, Sartorius AG, Partner (business rank), Research, Milbank, Cell, Transfection, Warburg Pincus, EBITDA, RTÉ Executive Board, Jefferies Group, Acquisition, Patient, Laboratory, Quality control, Growth, Jeantet, Gene, Sartorius, J. P. Morgan, Security (finance), Fine chemical, Management, Health care

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has signed an agreement to acquire Polyplus for approximately 2.4 billion euros from private investors including ARCHIMED and WP GG Holdings IV B.V., an affiliate of Warburg Pincus.

Key Points: 
  • The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has signed an agreement to acquire Polyplus for approximately 2.4 billion euros from private investors including ARCHIMED and WP GG Holdings IV B.V., an affiliate of Warburg Pincus.
  • Recording significant growth rates, Polyplus is expected to generate sales revenue in the upper double-digit million-euro range and a very substantial EBITDA margin in 2023.
  • Founded in 2001, Polyplus is based in Strasbourg, France, and has locations in France, Belgium, the U.S., and China.
  • Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies.

EQS-News: SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG

Retrieved on: 
Friday, March 31, 2023
Sartorius AG, Supervisory board, Sartorius, Annual general meeting, Security (finance)

At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 1.44 euros per preference share and 1.43 euros per ordinary share.

Key Points: 
  • At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 1.44 euros per preference share and 1.43 euros per ordinary share.
  • In the previous year, dividends were 1.26 euros per preference share and 1.25 euros per ordinary share.
  • This press release contains forward-looking statements about the future development of the Sartorius Group.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.

EQS-News: SARTORIUS AG: Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division

Retrieved on: 
Friday, March 31, 2023
Vaccine, Product management, Doctor of Philosophy, Marketing, Sartorius AG, Supervisory board, Research, ID Labs production discography, Human resource management, RTÉ Executive Board, Acquisition, Laboratory, China Pharmaceutical University, Quality control, Saint Petersburg, Sartorius, Pharmacology, Management

At today’s meeting, the Supervisory Board of Sartorius AG appointed Alexandra Gatzemeyer, Ph.D., as Member of the Executive Board, effective May 1, 2023.

Key Points: 
  • At today’s meeting, the Supervisory Board of Sartorius AG appointed Alexandra Gatzemeyer, Ph.D., as Member of the Executive Board, effective May 1, 2023.
  • After stepping down as Executive Board member as of June 16, 2023, Gerry Mackay will continue to support Sartorius in various cross-divisional tasks and initiatives.
  • Alexandra Gatzemeyer currently leads the LPS Sales & Services organization at Sartorius.
  • Dr. Lothar Kappich, Chairman of the Supervisory Board of Sartorius AG, thanked Gerry Mackay and welcomed Alexandra Gatzemeyer on behalf of the Board.

Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board

Retrieved on: 
Tuesday, March 28, 2023
Marketing, Institute of technology, Policy, Sartorius AG, Renã A. S. Robinson, Doctor of Philosophy, Chemistry, Euronext Paris, National Executive Board of the Boy Scouts of America, Euronext, Remuneration, Technical University of Munich, Management, Security (finance)

Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board

Key Points: 
  • Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
    René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
    In its meeting today, the Board of Directors of Sartorius Stedim Biotech S.A. appointed René Fáber, Deputy CEO and member of the Board of Directors, as Chief Executive Officer of Sartorius Stedim Biotech S.A., effective March 28, 2023.
  • René Fáber joined Sartorius Stedim Biotech S.A.’s parent company Sartorius AG in 2002 and held various leadership positions within its bioprocessing business, including in R&D and marketing.
  • In January 2019, he became a member of the Executive Board of Sartorius AG and Head of its Bioprocess Solutions division.
  • From March 28, 2023, onwards, the composition of the Board of Directors of Sartorius Stedim Biotech S.A. will be: Joachim Kreuzburg, Chairman; René Fáber, CEO1; Christelle Baudere; Pascale Boissel; Susan Dexter; Anne-Marie Graffin; Lothar Kappich; and Henri Riey.

Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing, Suggests BIS Research Study

Retrieved on: 
Friday, March 24, 2023
Analytik Jena, GE HealthCare, Gene, Sartorius AG, Merck Group, AAV, DSM-IV codes, Danaher Corporation, Becton, Dickinson and Company headquarters, Incidence, Name, Thermo Fisher Scientific, Investment, General Electric Company, Cancer, Cell, Getinge Group, Growth, Research, Exosome, FDA, Center for Urban and Regional Analysis, PCR, Wuxi, Software, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Fine chemical

FREMONT, Calif., March 24, 2023 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis. 

Key Points: 
  • FREMONT, Calif., March 24, 2023 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis.
  • According to this study, the global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is projected to reach $29.76 billion by 2031.
  • Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future."
  • The software solutions segment consists of all the software utilized from manufacturing to logistics in cell and gene therapy biomanufacturing.

Cell Culture Market worth $51.3 billion | MarketsandMarkets

Retrieved on: 
Thursday, March 2, 2023
Immune system, Danaher Corporation, Antibody, Corning Inc., Benchmarking, Thermo Fisher Scientific, Laboratory, Porter's generic strategies, Research, Regenerative medicine, Drug development, B cell, Animal, Cell, Merck Group, Investment, COVID-19, Infection, Growth, Key, Sartorius AG, Bioreactor, Antigen, Fine chemical, Vaccine, Pharmaceutical industry, Retail, Hook effect

Based on equipment, the cell culture market is segmented into supporting equipment, bioreactors, and storage equipment.

Key Points: 
  • Based on equipment, the cell culture market is segmented into supporting equipment, bioreactors, and storage equipment.
  • Cell culture involves the extensive use of laboratory equipment such as bioreactors, storage equipment, and cell culture-supporting equipment.
  • The monoclonal antibody production segment accounted for the largest share of the biopharmaceutical production segment in the cell culture market in 2022.
  • Based on biopharmaceutical production, the cell culture market is categorized into monoclonal antibody production, vaccine production, and other therapeutic protein production.

Cell Culture Market worth $51.3 billion | MarketsandMarkets

Retrieved on: 
Thursday, March 2, 2023
Immune system, Danaher Corporation, Antibody, Corning Inc., Benchmarking, Thermo Fisher Scientific, Laboratory, Porter's generic strategies, Research, Regenerative medicine, Drug development, B cell, Animal, Cell, Merck Group, Investment, COVID-19, Infection, Growth, Key, Sartorius AG, Bioreactor, Antigen, Fine chemical, Vaccine, Pharmaceutical industry, Retail, Hook effect

Based on equipment, the cell culture market is segmented into supporting equipment, bioreactors, and storage equipment.

Key Points: 
  • Based on equipment, the cell culture market is segmented into supporting equipment, bioreactors, and storage equipment.
  • Cell culture involves the extensive use of laboratory equipment such as bioreactors, storage equipment, and cell culture-supporting equipment.
  • The monoclonal antibody production segment accounted for the largest share of the biopharmaceutical production segment in the cell culture market in 2022.
  • Based on biopharmaceutical production, the cell culture market is categorized into monoclonal antibody production, vaccine production, and other therapeutic protein production.